We have recently developed DMS-MaPseq, which allows for targeted RNA structure probing in vivo at single molecule and single nucleotide resolution. First, cells are treated with DMS, which rapidly modifies unpaired adenines and cytosines. Unlike other chemical reagents, DMS is a very small molecule specific to the nitrogen atoms involved in Watson-Crick base-paring, which enables probing of RNA structure in the presence of RNA binding proteins. In the DMS-MaPseq technique, we use DMS concentrations that result in multiple modifications per single molecule. We then use a newly commercialized high fidelity and processive thermostable group II reverse transcriptase (TGIRT) enzyme, which converts DMS modifications into mutations in the cDNA. The cDNA is converted to dsDNA by PCR and then sequenced on an Illumina platform with long reads. Since the mutation background is negligible, the mutations within a single sequencing read correspond to the open bases within a single RNA molecule. There are two key advantages of using this approach compared to other chemical probing approaches: 1) we can selectively probe the structure of any RNA of interest, even at very low abundance, simply by using a RNA specific RT primer 2) we can analyze multiple DMS modification sites per RNA molecule, which allows us to distinguish heterogeneous RNA structure subpopulations in vivo. We use a combination of DMS-MaPseq and ribosome profiling to quantify the HIV-1 RNA structure and translation efficiency in cells.